Cargando…

Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma

Osteosarcoma (OS) is the most common malignant bone tumor in adolescents, and the clinical treatment of OS mainly includes surgery, radiotherapy, and chemotherapy. However, the side effects of chemotherapy drugs are an issue that clinicians cannot ignore. Nanomedicine and drug delivery technologies...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Haorui, Luo, Ping, Huang, Xiaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475588/
https://www.ncbi.nlm.nih.gov/pubmed/37670948
http://dx.doi.org/10.3389/fphar.2023.1269224
_version_ 1785100751362588672
author Zhang, Haorui
Luo, Ping
Huang, Xiaojun
author_facet Zhang, Haorui
Luo, Ping
Huang, Xiaojun
author_sort Zhang, Haorui
collection PubMed
description Osteosarcoma (OS) is the most common malignant bone tumor in adolescents, and the clinical treatment of OS mainly includes surgery, radiotherapy, and chemotherapy. However, the side effects of chemotherapy drugs are an issue that clinicians cannot ignore. Nanomedicine and drug delivery technologies play an important role in modern medicine. The development of nanomedicine has ushered in a new turning point in tumor treatment. With the emergence and development of nanoparticles, nanoparticle energy surfaces can be designed with different targeting effects. Not only that, nanoparticles have unique advantages in drug delivery. Nanoparticle delivery drugs can not only reduce the toxic side effects of chemotherapy drugs, but due to the enhanced permeability retention (EPR) properties of tumor cells, nanoparticles can survive longer in the tumor microenvironment and continuously release carriers to tumor cells. Preclinical studies have confirmed that nanoparticles can effectively delay tumor growth and improve the survival rate of OS patients. In this manuscript, we present the role of nanoparticles with different functions in the treatment of OS and look forward to the future treatment of improved nanoparticles in OS.
format Online
Article
Text
id pubmed-10475588
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104755882023-09-05 Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma Zhang, Haorui Luo, Ping Huang, Xiaojun Front Pharmacol Pharmacology Osteosarcoma (OS) is the most common malignant bone tumor in adolescents, and the clinical treatment of OS mainly includes surgery, radiotherapy, and chemotherapy. However, the side effects of chemotherapy drugs are an issue that clinicians cannot ignore. Nanomedicine and drug delivery technologies play an important role in modern medicine. The development of nanomedicine has ushered in a new turning point in tumor treatment. With the emergence and development of nanoparticles, nanoparticle energy surfaces can be designed with different targeting effects. Not only that, nanoparticles have unique advantages in drug delivery. Nanoparticle delivery drugs can not only reduce the toxic side effects of chemotherapy drugs, but due to the enhanced permeability retention (EPR) properties of tumor cells, nanoparticles can survive longer in the tumor microenvironment and continuously release carriers to tumor cells. Preclinical studies have confirmed that nanoparticles can effectively delay tumor growth and improve the survival rate of OS patients. In this manuscript, we present the role of nanoparticles with different functions in the treatment of OS and look forward to the future treatment of improved nanoparticles in OS. Frontiers Media S.A. 2023-08-21 /pmc/articles/PMC10475588/ /pubmed/37670948 http://dx.doi.org/10.3389/fphar.2023.1269224 Text en Copyright © 2023 Zhang, Luo and Huang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhang, Haorui
Luo, Ping
Huang, Xiaojun
Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma
title Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma
title_full Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma
title_fullStr Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma
title_full_unstemmed Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma
title_short Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma
title_sort engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475588/
https://www.ncbi.nlm.nih.gov/pubmed/37670948
http://dx.doi.org/10.3389/fphar.2023.1269224
work_keys_str_mv AT zhanghaorui engineerednanomaterialsenhancedrugdeliverystrategiesforthetreatmentofosteosarcoma
AT luoping engineerednanomaterialsenhancedrugdeliverystrategiesforthetreatmentofosteosarcoma
AT huangxiaojun engineerednanomaterialsenhancedrugdeliverystrategiesforthetreatmentofosteosarcoma